Lexatumumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Lexatumumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetTRAIL-R2
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6346H9832N1720O2002S42
Molar mass143601.02 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Lexatumumab (also known as ETR2-ST01) is an experimental agonistic human monoclonal antibody against TRAIL-R2 (DR5, APO-2), intended for the treatment of cancer.[1][2]

HGS-ETR2 antibodies were generated by Human Genome Sciences through a collaboration with Cambridge Antibody Technology.[3]

Development was discontinued in 2015.[4]

References[edit]

  1. ^ "Statement on a Nonproprietary Name adopted by the USAN Council - Lexatumumab" (PDF). American Medical Association. Archived from the original (PDF) on 2012-02-20.
  2. ^ Marini P (December 2006). "Drug evaluation: lexatumumab, an intravenous human agonistic mAb targeting TRAIL receptor 2". Current Opinion in Molecular Therapeutics. 8 (6): 539–46. PMID 17243490.
  3. ^ "TRAIL Receptor Antibodies". Human Genome Sciences, Inc. Archived from the original on 2008-05-16. Retrieved 2010-05-12.
  4. ^ "Lexatumumab". AdisInsight. Springer Nature Switzerland AG.